Inflammatory myopathies

Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

Brazilian patients with anti-MDA5(+) DM/ADM had a higher prevalence of skin and muscle involvement, whereas the prevalence of ILD and RP-ILD was significantly lower than in Japanese patients.

Study context

Population
Patients diagnosed with anti-MDA5(+) dermatomyositis (DM) or amyopathic DM at one Brazilian and two Japanese tertiary centres
Participants
34 vs 65
Exposure
Brazilian vs Japanese patients with anti-MDA5 DM/amyopathic DM (ADM)
  • Braziliann = 34
  • Japanesen = 65reference
Outcome
Phenotypic differences, with particular focus on interstitial lung disease (ILD)
Methodological detailsinternational, tricentric, longitudinal, one Brazilian and two Japanese tertiary centres, pre-standardised protocol
  • International
  • Tricentric
  • Longitudinal
  • One Brazilian and two Japanese tertiary centres
  • Pre-standardised protocol

Main finding

As reported in the abstract

Prevalence of ILD

P < 0.001

Observational data: associations, not effects.

Further findings

RP-ILD

P < 0.001

Age at diagnosis

Brazilian patients younger at diagnosis than Japanese

Clinical manifestations

Muscle weakness, myalgia, dysphagia, heliotrope rash, V-sign, calcinosis, RP and digital ulcers more prevalent in Brazilian patients
Mechanic's hands more prevalent in Japanese patients

Overall survival, relapses and complications (severe infection, malignancy)

Comparable between the two populations

Original publication

Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study. Clin Exp Rheumatol. Published 13 August 2024. doi:10.55563/clinexprheumatol/9s7djz

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.